查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600052

糖尿病藥物市場：按產品、應用和分銷管道 - 全球預測 2025-2030

Diabetes Drugs Market by Product (Insulin, Non-Insulin Injectable Drugs, Oral Drug), Application (Gestational Diabetes, Type 1 Diabetes, Type 2 Diabetes), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年糖尿病藥物市場規模為691.2億美元，預計2024年將達到729.7億美元，複合年成長率為5.88%，預計到2030年將達到1031.8億美元。

糖尿病藥物市場包括旨在改善糖尿病患者血糖值的藥物，包括第1型糖尿病、第2型糖尿病和妊娠糖尿病。由於久坐的生活方式、不健康的飲食和人口老化等因素，全球糖尿病盛行率不斷上升，這個市場變得越來越重要。抗糖尿病藥物的核心和最終用途範圍包括血糖值管理，以降低急性和長期併發症的風險並改善患者的生活品質。根據市場洞察，關鍵的成長要素包括藥物配方的持續進步、糖尿病管理意識的提高以及對醫療基礎設施的大量投資。此外，新興國家糖尿病盛行率的不斷上升也為市場擴張提供了潛在的機會。最新的商機可以在提供個人化醫療和全面糖尿病管理解決方案的數位工具的開發中找到。然而，阻礙市場成長的挑戰包括嚴格的法律規範、與糖尿病藥物相關的副作用以及可能限制低收入地區獲得的先進治療的高成本。潛在的創新領域包括增強智慧胰島素筆等藥物傳遞系統，以及將人工智慧融入糖尿病管理以改善治療結果。此外，SGLT2 抑制劑和 GLP-1 受體促效劑等新型治療藥物的開發持續塑造市場格局。另外值得注意的是，製藥公司和高科技公司之間的合作可以促進創造更具創新性的綜合解決方案。簡而言之，在技術進步以及對更有效率、更容易獲得的糖尿病治療解決方案日益成長的需求的推動下，市場充滿活力且充滿潛力。然而，抓住這些機會需要克服監管和成本障礙，凸顯了研發策略投資對推動業務成長的重要性。

主要市場統計
基準年[2023] 691.2億美元
預測年份 [2024] 729.7億美元
預測年份 [2030] 1031.8億美元
複合年成長率（%） 5.88%

市場動態：揭示快速發展的糖尿病藥物市場的關鍵市場洞察

供需的動態交互作用正在改變糖尿病藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球糖尿病盛行率不斷上升
    • 政府針對糖尿病的措施和支持性衛生政策
    • 活性化先進配方的研發
  • 市場限制因素
    • 糖尿病藥物高成本，糖尿病管理複雜
  • 市場機會
    • 建立實驗室與製藥公司之間的合作關係
    • 消費者對個人化醫療的需求不斷成長
  • 市場挑戰
    • 嚴格的政府核准流程

波特五力：駕馭糖尿病藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解糖尿病藥物市場的外部影響

外部宏觀環境因素在塑造糖尿病藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解糖尿病治療市場的競爭狀況

糖尿病藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣式糖尿病藥物市場供應商的績效評估

FPNV定位矩陣是評估糖尿病治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪糖尿病治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，糖尿病治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球糖尿病盛行率正在上升
      • 政府針對糖尿病的措施和支持性衛生政策
      • 擴大先進藥物配方的研發活動
    • 抑制因素
      • 糖尿病藥物高成本，糖尿病管理複雜
    • 機會
      • 研究實驗室與製藥公司之間的新合作
      • 消費者對個人化醫療的需求增加
    • 任務
      • 嚴格的政府核准流程
  • 市場區隔分析
    • 產品：消費者對長效胰島素藥物的需求不斷增加
    • 應用：越來越多用於治療第2型糖尿病
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章糖尿病藥物市場：依產品

  • 胰島素
    • 中效胰島素
    • 長效胰島素
    • 混合胰島素
    • 速效胰島素
    • 速效胰島素
  • 除胰島素外的注射藥物
    • Amylin 類似物
    • GLP-1受體促效劑
  • 口服藥物
    • 雙胍
    • DPP-4抑制劑
    • SGLT-2抑制劑
    • 磺醯尿素類
    • 胰島素增敏劑

第7章糖尿病藥物市場：依應用分類

  • 妊娠糖尿病
  • 1型糖尿病
  • 2型糖尿病

第8章糖尿病藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章北美和南美糖尿病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區糖尿病藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲糖尿病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 禮來公司糖尿病治療藥物替澤帕肽在中國獲得核准
    • 賽諾菲印度公司推出了 Soliqua，一種治療 2 型糖尿病和肥胖症的藥物，旨在簡化治療並提高依從性。
    • Lupin 獲得美國FDA核准非專利藥糖尿病藥物，目標是透過具有競爭力的定價和策略性擴張，實現每年 500 萬美元的美國市場
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer AG
  • Biocon Limited
  • Bioton SA
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Eva Pharma
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Gulf Pharmaceutical Industries（Julphar）
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • MannKind Corporation
  • Merck & Co., Inc.
  • MJ Biopharm Pvt. Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-434CCDA051C3

The Diabetes Drugs Market was valued at USD 69.12 billion in 2023, expected to reach USD 72.97 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 103.18 billion by 2030.

The diabetes drugs market encompasses pharmaceuticals aiming to improve blood sugar levels in individuals with diabetes, including type 1, type 2, and gestational diabetes. This market has become increasingly crucial as the prevalence of diabetes globally is rising due to factors like sedentary lifestyles, unhealthy diets, and aging populations. The core applications and end-use scope of diabetes drugs involve managing blood glucose levels to mitigate the risk of acute and long-term complications, improving the quality of life for patients. Market insights reveal that key growth influencers include the continuous advancements in drug formulation, increasing awareness about diabetes management, and substantial investments in healthcare infrastructure. Moreover, the increasing incidence of diabetes in emerging economies presents potential opportunities for market expansion. Latest opportunities can be found in the development of personalized medicine and digital tools that offer comprehensive diabetes management solutions. However, limitations challenging market growth include stringent regulatory frameworks, side effects associated with diabetes medication, and the high cost of advanced therapeutic drugs, which may limit access in low-income regions. Areas poised for innovation include enhancing drug delivery systems, such as smart insulin pens, and the integration of artificial intelligence in diabetes management to enhance therapeutic outcomes. Furthermore, the development of novel therapeutic classes, including SGLT2 inhibitors and GLP-1 receptor agonists, continues to shape the market landscape. It's also noteworthy that collaboration between pharmaceutical companies and tech firms could facilitate the creation of more innovative, integrated solutions. In essence, the market is dynamic and ripe with potential, driven by technological advances and a growing need for more efficacious and accessible diabetic care solutions. However, capturing these opportunities necessitates overcoming regulatory and cost barriers, emphasizing the importance of strategic investment in research and development to propel business growth.

KEY MARKET STATISTICS
Base Year [2023] USD 69.12 billion
Estimated Year [2024] USD 72.97 billion
Forecast Year [2030] USD 103.18 billion
CAGR (%) 5.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetes Drugs Market

The Diabetes Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of diabetes globally
    • Government Initiatives and supportive health policies for diabetes
    • Growing research and development activities for advanced drug formulations
  • Market Restraints
    • High cost of diabetes medications and complexity of diabetes management
  • Market Opportunities
    • Emerging collaborations among research labs and pharmaceutical companies
    • Rising demand for personalized medicine among consumers
  • Market Challenges
    • Stringent government approval procedures

Porter's Five Forces: A Strategic Tool for Navigating the Diabetes Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetes Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetes Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetes Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetes Drugs Market

A detailed market share analysis in the Diabetes Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetes Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetes Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetes Drugs Market

A strategic analysis of the Diabetes Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetes Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Baxter International, Inc., Bayer AG, Biocon Limited, Bioton S.A., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Eva Pharma, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Gulf Pharmaceutical Industries (Julphar), Johnson & Johnson Services, Inc., Lupin Limited, MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Diabetes Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Insulin, Non-Insulin Injectable Drugs, and Oral Drug. The Insulin is further studied across Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin, Rapid-Acting Insulin, and Short-Acting Insulin. The Non-Insulin Injectable Drugs is further studied across Amylin Analogs and GLP-1 Receptor Agonists. The Oral Drug is further studied across Biguanides, DPP-4 inhibitors, SGLT-2 inhibitors, Sulfonylureas, and Thiazolidinediones.
  • Based on Application, market is studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diabetes globally
      • 5.1.1.2. Government Initiatives and supportive health policies for diabetes
      • 5.1.1.3. Growing research and development activities for advanced drug formulations
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diabetes medications and complexity of diabetes management
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging collaborations among research labs and pharmaceutical companies
      • 5.1.3.2. Rising demand for personalized medicine among consumers
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government approval procedures
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising demand for long-acting insulin drugs among consumers
    • 5.2.2. Application: Increasing application for treatment of type 2 diabetes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetes Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Insulin
    • 6.2.1. Intermediate-Acting Insulin
    • 6.2.2. Long-Acting Insulin
    • 6.2.3. Premixed Insulin
    • 6.2.4. Rapid-Acting Insulin
    • 6.2.5. Short-Acting Insulin
  • 6.3. Non-Insulin Injectable Drugs
    • 6.3.1. Amylin Analogs
    • 6.3.2. GLP-1 Receptor Agonists
  • 6.4. Oral Drug
    • 6.4.1. Biguanides
    • 6.4.2. DPP-4 inhibitors
    • 6.4.3. SGLT-2 inhibitors
    • 6.4.4. Sulfonylureas
    • 6.4.5. Thiazolidinediones

7. Diabetes Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Gestational Diabetes
  • 7.3. Type 1 Diabetes
  • 7.4. Type 2 Diabetes

8. Diabetes Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Diabetes Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diabetes Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diabetes Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Eli Lilly gains approval for diabetes drug Tirzepatide in China
    • 12.3.2. Sanofi India launches Soliqua for Type 2 diabetes and obesity, aiming to simplify treatment and improve compliance
    • 12.3.3. Lupin secures USFDA approval for a generic diabetes drug, targets USD 5 million annual US market with competitive pricing and strategic expansion
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. Baxter International, Inc.
  • 5. Bayer AG
  • 6. Biocon Limited
  • 7. Bioton S.A.
  • 8. Boehringer Ingelheim International GmbH
  • 9. Bristol-Myers Squibb Company
  • 10. Eli Lilly and Company
  • 11. Eva Pharma
  • 12. GlaxoSmithKline PLC
  • 13. Glenmark Pharmaceuticals Limited
  • 14. Gulf Pharmaceutical Industries (Julphar)
  • 15. Johnson & Johnson Services, Inc.
  • 16. Lupin Limited
  • 17. MannKind Corporation
  • 18. Merck & Co., Inc.
  • 19. MJ Biopharm Pvt. Ltd.
  • 20. Novartis AG
  • 21. Novo Nordisk A/S
  • 22. Oramed Pharmaceuticals Inc.
  • 23. Pfizer Inc.
  • 24. Sanofi S.A.
  • 25. Takeda Pharmaceutical Company Limited
  • 26. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 27. Viatris Inc.
  • 28. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. DIABETES DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETES DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETES DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES DRUGS MARKET SIZE, BY SGLT-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DIABETES DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 285. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023